REGN — Regeneron Pharmaceuticals, Inc.
$955.47
+$4.28 (+0.45%)
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
Market Cap
$98.84B
Forward P/E
13.5x
52-Week Range
N/A
REGN Price History
Revenue vs. Net Income
$14.3B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$3.8B
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
14.6%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
4.4x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
8.5%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
-5.6%
Net buyback · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
